Abstract | BACKGROUND: AIM: METHODS: MEDLINE, EMBASE and the Cochrane central register of controlled trials were searched (up to December 2014). Randomised placebo-controlled trials of anti- integrin antibodies in adults with active or quiescent CD or UC were eligible. Dichotomous data were pooled to obtain a relative risk (RR) of opportunistic infection or malignancy, with 95% confidence intervals (CIs). RESULTS: CONCLUSIONS: Absolute numbers of opportunistic infections were higher with anti- integrin antibodies, but this difference is not statistically significant. There was no increased risk of malignancy detected. Long-term data in large prospective cohorts are needed to further assess this issue.
|
Authors | P Luthra, L Peyrin-Biroulet, A C Ford |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 41
Issue 12
Pg. 1227-36
(Jun 2015)
ISSN: 1365-2036 [Electronic] England |
PMID | 25903741
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2015 John Wiley & Sons Ltd. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Integrins
- Natalizumab
- vedolizumab
|
Topics |
- Adult
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
(immunology, therapeutic use)
- Clinical Trials as Topic
- Colitis, Ulcerative
(drug therapy)
- Crohn Disease
(drug therapy)
- Humans
- Inflammatory Bowel Diseases
(drug therapy)
- Integrins
(administration & dosage, immunology, therapeutic use)
- Natalizumab
- Neoplasms
(chemically induced)
- Opportunistic Infections
(chemically induced)
- Prospective Studies
|